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QuPath: Open source software for 
digital pathology image analysis
Peter Bankhead1, Maurice B. Loughrey1,2, José A. Fernández1, Yvonne Dombrowski3,  
Darragh G. McArt1, Philip D. Dunne  1, Stephen McQuaid1,2, Ronan T. Gray4, Liam J. Murray4, 
Helen G. Coleman4, Jacqueline A. James1,2, Manuel Salto-Tellez1,2 & Peter W. Hamilton1
QuPath is new bioimage analysis software designed to meet the growing need for a user-friendly, 
extensible, open-source solution for digital pathology and whole slide image analysis. In addition to 
offering a comprehensive panel of tumor identification and high-throughput biomarker evaluation 
tools, QuPath provides researchers with powerful batch-processing and scripting functionality, and an 
extensible platform with which to develop and share new algorithms to analyze complex tissue images. 
Furthermore, QuPath’s flexible design makes it suitable for a wide range of additional image analysis 
applications across biomedical research.
The ability to acquire high resolution digital scans of entire microscopic slides with high-resolution whole slide 
scanners is transforming tissue biomarker and companion diagnostic discovery through digital image analytics, 
automation, quantitation and objective screening of tissue samples. This area has become widely known as digital 
pathology1,2. Whole slide scanners can rapidly generate ultra-large 2D images or z-stacks in which each plane 
may contain up to 40 GB uncompressed data. Manual subjective scoring of this data by traditional pathologist 
assessment is no longer sufficient to support large-scale tissue biomarker trials, and cannot ensure the high qual-
ity, reproducible, objective analysis essential for reliable clinical correlation and candidate biomarker selection. 
New and powerful software tools are urgently required to ensure that pathological assessment of tissue is practi-
cal, accessible and reliable for biological discovery and the development of clinically-relevant tissue diagnostics.
In recent years, a vibrant ecosystem of open source bioimage analysis software has developed. Led by ImageJ3, 
researchers in multiple disciplines can now choose from a selection of powerful tools, such as Fiji4, Icy5, and 
CellProfiler6, to perform their image analyses. These open source packages encourage users to engage in further 
development and sharing of customized analysis solutions in the form of plugins, scripts, pipelines or work-
flows – enhancing the quality and reproducibility of research, particularly in the fields of microscopy and high 
content imaging. This template for open-source development of software has provided opportunities for image 
analysis to add considerably to translational research by enabling the development of the bespoke analytical 
methods required to address specific and emerging needs, which are often beyond the scope of existing com-
mercial applications7. However, none of the aforementioned software applications tackle the specific visualiza-
tion and computational challenges posed by whole slide images (WSI) and very large 2D data. Rather, open 
source tools for digital pathology to date have comprised libraries to handle digital slide formats (e.g. OpenSlide8, 
Bio-Formats9), software to crop whole slide images into manageable tiles or perform analysis on such cropped 
tiles (e.g. SlideToolKit10, ImmunoRatio11), or web platforms for data management and collaborative analysis (e.g. 
Cytomine12). While each of this makes a valuable contribution, the field continues to lack a commonly-accepted, 
open software framework for developing and distributing novel digital pathology algorithms in a manner that is 
immediately accessible for any researcher or pathologist. In practice, this has meant that users without access to 
expensive commercial solutions have had to either resort to inefficient workarounds (such as image downsam-
pling and cropping) to apply limited quantitative analysis using general open source analysis tools to a subset of 
their data10,13, or to rely primarily on laborious manual evaluation of slides, which is known to have high variabil-
ity and limited reproducibility14,15. It has also made it more difficult for computational researchers to innovate in 
algorithm development, and to make state-of-the-art analysis methods widely available16.
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QuPath (https://qupath.github.io) has been developed to address these needs by offering the first comprehen-
sive, open source desktop software application specifically designed to analyze and explore whole slide imaging 
data. At its core is a cross-platform, multithreaded, tile-based whole slide image viewer, which incorporates exten-
sive annotation and visualization tools. On top of this, QuPath offers an array of novel algorithms to provide not 
only ready-made, user-friendly solutions to common, challenging analysis problems in pathology, but also the 
building blocks to create custom workflows – and link these together for batch processing with powerful scripting 
functionality (Fig. 1). Finally, QuPath enables developers to add their own extensions to solve new challenges and 
applications, and to exchange data in a streamlined manner with existing tools that otherwise provide limited 
whole slide support, such as ImageJ and MATLAB.
A key feature underpinning QuPath’s functionality, and a major technical distinguishing factor between 
QuPath and other bioimaging analysis software, is its hierarchical, ‘object-based’ data model. Here, an ‘object’ 
refers primarily to a structure or region within the image, which may be created and manipulated by either inter-
active drawing tools (e.g. to annotate a particular region of interest) or automated segmentation commands (e.g. 
to detect individual nuclei or cells). However, in addition to representing a region of interest, objects can also be of 
different types (e.g. detection, annotation) and support the assignment of classifications, measurements and links 
to ‘parent’ and ‘child’ objects in a manner that can be rapidly queried and manipulated using built-in command or 
scripting. This generic model allows QuPath to represent and display relationships between very large numbers 
of image objects in an efficient and intuitive manner across gigapixel images, and support the fast and interactive 
training of object classifiers using machine learning techniques.
A practical example of this is in the evaluation of the presence, localization and intensity of expression of 
key diagnostic, prognostic and predictive biomarkers in tissue sections. These biomarkers are typically detected 
using antibodies and chromogenic based detection systems, and are selectively expressed in tumor cells or in 
Figure 1. Illustration of QuPath’s use and functionality. (a) A typical workflow for TMA analysis (here, p53) 
demonstrates several of QuPath’s main features (left-to-right): Creation of a multi-slide project with automated 
TMA dearraying, stain estimation, cell detection and feature computation, trainable cell classification, batch 
processing, and survival analysis. (b) QuPath offers a wide range of additional functionality, including support 
for whole face tissue sections and fluorescence image analysis, data exchange with existing software and 
platforms (e.g. ImageJ and MATLAB), scriptable data mining, and rapid generation, visualization and export of 
spatial, morphological and intensity-based features.
www.nature.com/scientificreports/
3SCIENTIfIC REPORTS | 7: 16878  | DOI:10.1038/s41598-017-17204-5
other cellular compartments. QuPath’s built-in cell segmentation algorithms can detect potentially millions of 
cells as objects within a single WSI, in addition to measuring cell morphology and biomarker expression. QuPath 
further supports the classification of different cell types according to these features, to generate a comprehensive 
phenotypic description of each cell within the tissue sample. This in turn provides a quantitative cellular map of 
the entire tissue section, which can be subsequently selected, queried and filtered to mine the image data and 
uncover morphological subtleties not immediately visible during traditional pathological assessment. All of this 
can typically be achieved within minutes, without a requirement for specialist hardware.
Results and Discussion
To demonstrate some of these capabilities, including its biological and clinical validity, we used QuPath to analyze 
several image sets derived from surgical resection specimens from a population-based cohort of 660 patients 
with stage II and stage III colon cancer, diagnosed between 2004–2008 (392 stage II, 268 stage III) and with 
high-quality curation of clinicopathological information. From representative paraffin-embedded tumor blocks, 
provided via the Northern Ireland Biobank, whole sections were haematoxylin and eosin-stained in the Northern 
Ireland Molecular Pathology Laboratory. Tissue microarrays (TMAs) were generated from representative 1 mm 
diameter tumor cores from each case, sampled in triplicate from the tumor center after annotation.
The aim was to test the performance of QuPath in the context of known and novel biological and clinical data, 
using cancer immunology and tumor suppressor genes as paradigms. Firstly, we applied QuPath to analyze TMAs 
immunohistochemically-stained (IHC) for the T cell markers CD3 and CD8. Following digital scanning of the 
WSI, the initial QuPath setup required importing the images, applying automated ‘dearraying’ to identify tissue 
cores, manually refining the resulting dearrayed grid, and removing cores unsuitable for analysis. After this step, 
batch analysis was applied across all TMA slides to identify the tissue within each core and automatically count 
the number of positive cells per mm2 tissue based upon a fast peak-finding algorithm after stain separation by 
color deconvolution17 (Supplementary Fig. 1, Supplementary Video 1). Running on a standard Mac Pro (3.5 GHz, 
6-Core Intel Xeon E5, 32-GB RAM), this approach required less than 4 minutes for each biomarker to analyze 
21 whole slide images, representing a total of >2000 tissue cores per biomarker and counting approximately 1.2 
million CD3 positive and 0.6 million CD8 positive cells, while simultaneously exporting low-resolution images of 
each core both with and without markup for verification. After applying a median cutoff to the exported results, a 
statistically significant association between disease-specific survival and positive cell density scores was demon-
strated for both CD3 and CD8 (log-rank test, p-values 0.006 and 0.007 respectively; Fig. 2a,b). This recapitulates 
within our cohort the seminal work of Galon et al. in demonstrating the prognostic relevance of adaptive immu-
nity in colorectal cancer18, while demonstrating a highly-efficient method of investigating similar markers within 
other cohorts and cancer types.
Next, we used QuPath to evaluate immunohistochemistry for p53 in a second set of TMAs from the same 
cohort. This required a more sophisticated analysis to encompass the biological understanding and staining 
pattern of the marker. After applying QuPath’s cell detection algorithm to segment and measure cells within 
each core, a random trees classifier19 was interactively trained to enable p53 expression to be scored selectively 
within the epithelial cell population according to nuclear staining intensity and proportion (Supplementary Fig. 2, 
Figure 2. Survival analysis of colon cancer cohort based on QuPath automated image analysis. (a–d) Kaplan 
Meier survival analysis for biomarker scores of TMAs stained for CD3, CD8, p53 and PD-L1. Median cutoffs 
are applied in all cases, except p53 where two cutoffs were selected by an experienced pathologist to distinguish 
between aberrant negative, “wild type” (normal) and aberrant positive groups. Representative images showing 
an original core and QuPath markup image are included below. (e) Kaplan Meier curve showing patient 
stratification based on median tumor stromal percentage. Representative images show the original images and 
markup for tumors with a high and low stromal percentage respectively. Green indicates regions classified as 
stroma, dark red indicates tumor epithelium, while yellow represents other classified tissue or whitespace.
www.nature.com/scientificreports/
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Supplementary Video 2). This analysis showed that aberrant p53 expression (diffuse intense or completely absent 
immunoreactivity) is associated with significantly poorer unadjusted disease-specific survival when compared 
with intermediate, ‘wild-type’ expression (p = 0.003 extreme negative/positive vs. intermediate; Fig. 2c). Despite 
the well-established role of TP53 in colorectal cancer carcinogenesis, results from prognostic studies assessing 
p53 IHC expression have been inconsistent20. However, the extreme negative pattern of aberrant p53 immuno-
reactivity has only been described relatively recently21,22 and has not been widely assessed in colorectal cancer 
cohorts. This example therefore emphasises the flexibility of the QuPath open source platform in measuring 
common IHC markers with variable tumor expression patterns, and demonstrates how the relationship between 
quantitative cellular analysis and clinical outcome can be robustly assessed.
We then applied QuPath to the analysis of programmed cell death ligand 1 (PD-L1) immunoexpression in the 
same TMA cohort. PD-L1 immunoexpression is a prognostic marker in a range of cancer types and also a predic-
tor of response to immune checkpoint therapy in some cancers23,24. However, there is a lack of consensus on the 
epitopes of clinical relevance and, more importantly, the optimal scoring systems for evaluation. The approach to 
analysis was similar in principle to that adopted for p53, however further attention was required because of addi-
tional challenges posed by PD-L1 immunostaining. Firstly, staining is cytoplasmic and/or membranous rather 
than nuclear. Secondly, PD-L1 can be expressed in tumor epithelium, but is more commonly expressed in other 
tissue compartments, notably within peritumoral stromal inflammatory cells. Although this level of heterogeneity 
in staining pattern is increasingly being recognised, the clinical importance of distinguishing tumor epithelial 
from inflammatory cell staining is yet to be fully understood. Sufficient cell classification is therefore required to 
identify both positively and negatively staining tumor (epithelial) and non-tumor cell populations, in addition to 
distinguishing true protein expression levels from the various staining artefacts that are inherent with IHC-based 
tissue analysis. Here, applying QuPath, a cell was classified as positive or negative based on maximal DAB stain-
ing intensity, as a surrogate marker of protein expression, within a full cell region approximated by expanding 
detected nuclei (Supplementary Fig. 3). The percentage of all cells exhibiting PD-L1 positivity was calculated for 
each TMA core to give a summary PD-L1 score for that core. A median cutoff of 1.46% positive cells was deter-
mined from across the cohort to stratify patients, showing higher PD-L1 expression to be significantly associated 
with improved disease-specific survival in unadjusted analysis (p = 0.004, Fig. 2d). Additionally, an analysis based 
on tertiles exhibited a dose-response effect, and separation of the tumor (epithelial) and non-epithelial compo-
nents suggested that PD-L1 expression in colon cancer tissue is primarily found in the non-epithelial compart-
ment (Supplementary Fig. 4). These results support the incipient evidence of PD-L1 prognostic value in colorectal 
cancer reported by ourselves and others in independent cohorts24–26, and may be of help when used together with 
tumor microsatellite instability status for patient stratification in consideration of anti-PD-L1 therapy.
Finally, to demonstrate QuPath’s flexibility beyond IHC scoring in TMAs, we applied texture-based analysis 
to calculate the tumor stromal percentage in whole face representative tumor sections stained with hematoxylin 
and eosin (H&E) from 312 patients with stage II colon cancer from the same cohort. Several studies have reported 
that a higher intratumoral stromal percentage correlates with a worse prognosis in patients with stage II and stage 
III colorectal cancer27,28. Given highly variable clinical outcomes within stage II disease, there is a particular need 
for additional prognostic features in this group, to identify those patients most likely to benefit from adjuvant 
chemotherapy. These studies employed a crude visual estimate of tumor stromal percentage. Applying QuPath’s 
more fine-grained and reproducible assessment, and a median cutoff for analysis, we found lower disease-specific 
survival among patients with a high tumor stromal percentage in unadjusted analysis (p = 0.013; Fig. 2e), consist-
ent with previous findings27,28.
In summary, QuPath represents a uniquely comprehensive, user-friendly, open source bioimage analysis 
platform designed for whole slide images. We have demonstrated that it provides the tools necessary for fast, 
accurate and reproducible digital pathology analysis across a range of challenging applications. All of the above 
represent analyses that are cumbersome and time-consuming for pathologists to perform manually, given that 
they depend upon the accurate visual estimation of proportional staining within large numbers of stained cells, 
or of proportional composition of complex tissue areas. Accurate assessment is particularly difficult when the 
clinically relevant cutoff is very low and expression very localized (e.g. PD-L1), requiring detailed examination 
and precision. Such precise analyses are becoming increasingly necessary and important, both clinically in the era 
of personalized medicine, and in a research context for high-throughput evaluation of novel biomarkers. By offer-
ing an extensible environment for pathologists, biologists, and computer scientists to build highly performant 
algorithms for image interpretation and analysis, there is potential to drive adoption of quantitative imaging in 
academic, diagnostic and pharmaceutical research organizations, and to accelerate biomarker discovery in large 
scale multinational clinical trials. This is an absolute requirement to ensure a return on the global investment 
made in companion diagnostics for precision medicine.
Materials and Methods
Cohort. This analysis was based on a population-based cohort of 660 stage II/III colon adenocarcinoma 
patients, representing 89% of all patients undergoing surgery for stage II/III colon adenocarcinoma in two 
Healthcare Trusts in Northern Ireland between 2004 and 2008. Patients were sampled and clinical information 
obtained from the Northern Ireland Cancer Registry. All patients were followed up for occurrence and cause of 
death via linkage to the Northern Ireland Registrar General’s Office up to 31st December 2013. Ethical approval 
for these linkages was given by ORECNI (REC: 10/NIR02/53). Over ten years (and a mean of 5 years) of clin-
ical follow-up, 46% of patients had died, of which 38% were from CRC-specific causes. Corresponding tumor 
slides and blocks were retrieved and collated via the Northern Ireland Biobank which has ethical approval to use 
de-identified tissue samples from the Belfast Health and Social Care Tissue Pathology archive (REC:11/NI/0013).
This study was conducted in accordance to REporting recommendations for tumour MARKer prognostic 
studies (REMARK)29. The reporting standards of the current study fulfill these recommendations.
www.nature.com/scientificreports/
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Following slide review, a new section was cut for H&E staining from a single representative tumor block in 
each case, and the new slides annotated for tissue microarray (TMA) construction. Three representative areas 
within the tumor center of each block were annotated for targeted coring (by an experienced biomedical scientist 
and confirmed by expert pathologists, MBL and JAJ). One millimeter diameter tissue cores were extracted from 
donor blocks and inserted into recipient blocks using a manual tissue arrayer (Estigen, Tartu, Estonia).
Immunohistochemistry. All IHC was performed in a hybrid laboratory (Northern Ireland Molecular 
Pathology Laboratory) that has UK Clinical Pathology Accreditation. Internally validated biomarker conditions, 
which followed UK-NEQAS guidelines (CD3 and CD8) or were based on expected performance from the lit-
erature (p53 and PD-L1), were as follows: CD3 (clone 2GV6 Ventana BenchMark; CC1 32 minutes, Optiview 
detection), CD8 (clone c8/144B, Dako: Leica Bond III, ER2 20 mins, 1/50, polymer detection), p53 (clone DO-7, 
Dako, ER2 30 mins, 1/100, polymer detection), PD-L1 (clone SP142, Ventana BenchMark, CC1 24 mins, optiview 
detection).
Image data acquisition. All TMA slides were scanned using an Aperio ScanScope CS whole slide scan-
ner at 40X magnification, with a resolution of 0.25 μm/pixel. H&E slide scanning was heterogenous: 231 were 
scanned on the Aperio ScanScope scanner, while 81 were scanned on a Hamamatsu Nanozoomer. The resolution 
of all images was within the range 0.231–0.253 μm/pixel.
Software. QuPath was written as a novel, cross-platform Java application. The core software was developed 
using Java 8, with a user interface written using JavaFX. Whole slide image reading made use of QuPath’s inter-
faces to the OpenSlide library8, while the implementations of QuPath’s cell detection and superpixel segmentation 
commands made use of ImageJ as a library for standard image processing operations3. The random trees classifier 
and fast cell counting were implemented using the OpenCV library (http://opencv.org). The analysis for this study 
was performed on a Mac Pro (3.5 GHz, 6-Core Intel Xeon E5, 32-GB RAM).
Code availability. Source code and documentation for QuPath are available at https://qupath.github.io.
Statistical analysis. Survival curves using the Kaplan Meier method were generated and log-rank tests 
applied using the TMA data viewer within QuPath, and independently verified using R (version 3.2.2)30 with the 
‘Survival’ package (version 2.38–3)31. For the calculation of disease-specific survival, deaths from other causes 
were treated as censored events. Median cutoff values were used in all cases, except for p53 where an experienced 
pathologist (MBL) selected two biologically-plausible cutoffs (H-scores 10 and 160) to separate extreme posi-
tive and extreme negative cases from those with intermediate (‘wild-type’) expression, based upon viewing all 
TMA cores post-analysis ranked by H-score. Stratification based on tertiles is also provided in the Supplementary 
Materials for PD-L1.
For TMA analysis, up to three tissue cores were available from each tumor, all selected from the same paraffin 
block representing the central tumor region. A single patient biomarker score was defined as the median of all 
available scores for the corresponding patient and biomarker. The median was chosen to aid the robustness of 
the measurement in a high-throughput setting, and reduce the likelihood of basing the score for any individual 
patient on an outlier that may have been caused by a tissue or staining artefact.
Tissue microarray preprocessing. Separate projects were created within QuPath for each biomarker, and 
the slide images imported to the corresponding projects. QuPath’s automated TMA dearrayer was applied in 
batch over all slides within each project to identify tissue cores. The resulting TMA grid was manually verified 
and amended where necessary, e.g. to adjust the locations of cores that were outside their expected position, or to 
remove cores where prominent artefacts were visible. Patient identifiers were then imported into QuPath for each 
core to assist alignment with survival data later. Additionally, stain vector (i.e. color) and background estimates 
were applied for each IHC analysis project to improve stain separation within QuPath using color deconvolu-
tion17. This was achieved by selecting a representative area containing an area of background along with examples 
of strong hematoxylin and DAB staining, and applying QuPath’s Estimate stain vectors command to identify stain 
vectors within this region. The resulting vectors were then used for all images in the project.
Analysis of CD3 and CD8 IHC. After the initial TMA preprocessing steps described above, analysis of CD3 
and CD8 was performed using QuPath’s Simple tissue detection and Fast cell counts commands. Briefly, tissue 
was detected within each TMA core by thresholding a downsampled and smoothed image of the core, followed 
by cleanup of the resulting binary image by morphological operations. Individual cells were identified by sepa-
rating stains using color deconvolution and identifying peaks in either the hematoxylin channel (CD3) or sum 
of the hematoxylin and DAB channels (CD8) after smoothing, and assigning these as positive or negative cells 
based upon the smoothed DAB channel information. The number of positive cells and area detected were used 
to calculate the average number of positive cells per mm2, and these results exported along with markup images 
showing the detected cells, for visual verification. The detection and export steps were fully automated using a 
batch processing script.
Analysis of p53 IHC. Preprocessing steps were applied as described above. QuPath’s Cell detection command 
was then used to identify cells across all cores based upon nuclear staining. This command additionally estimates 
the full extent of each cell based upon a constrained expansion of the nucleus region, and calculates up to 33 
measurements of intensity and morphology, including nucleus area, circularity, staining intensity for hematoxylin 
and DAB, and nucleus/cell area ratio. Because not all of these measurements are expected to provide independ-
ent or useful information with regard to cell classification, a subset of 16 measurements was chosen empirically 
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and supplemented for each cell by measuring the local density of cells, and taking a Gaussian-weighted sum of 
the corresponding measurements within neighboring cells using QuPath’s Add smoothed features command. A 
two-way random trees classifier was then interactively trained to distinguish tumor epithelial cells from all other 
detections (comprising non-epithelial cells, necrosis, or any artefacts misidentified as cells) and applied across all 
slides (see Supplementary Video 2). Intensity thresholds were set to further subclassify tumor cells as being neg-
ative, weak, moderate or strongly positive for p53 staining based upon mean nuclear DAB optical densities. An 
H-score was calculated for each tissue core by adding 3x% strongly stained tumor nuclei, 2x% moderately stained 
tumor nuclei, and 1x% weakly stained tumor nuclei32, giving results in the range 0 (all tumor nuclei negative) to 
300 (all tumor nuclei strongly positive).
Analysis of PD-L1 IHC. The approach to scoring PD-L1 was similar to p53, apart from the following: 1) a 
three-way random trees classifier was trained to distinguish between epithelial, non-epithelial and ‘other’ detec-
tions (including artefacts and necrosis); 2) cells were classified as positive or negative based upon a single intensity 
threshold applied to the maximum DAB optical density within the full cell area, and 3) summary scores were 
generated as the percentage of cells classified as positive, with ‘other’ detections removed.
Analysis of tumor stromal percentage in H&E whole face sections. Representative tumor regions 
were annotated across all 312 H&E-stained slides by an experienced pathologist (MBL) using QuPath’s manual 
annotation tools. A script was then applied in batch to automatically identify and set the average background 
intensity for the red, green and blue channels of each image, which varied markedly according to the scanner 
used. A second script was then run over all images to apply QuPath’s SLIC superpixel segmentation command to 
subdivide each annotated region into ‘superpixels’ based upon simple linear iterative clustering33. This script addi-
tionally calculated both the average hue for each superpixel along with Haralick texture features34 from optical 
density values using QuPath’s Add intensity features command. QuPath’s Add smoothed features command was 
also applied to calculate a Gaussian-weighted sum of the features of neighboring superpixels, and append these 
to the existing features for each superpixel. This provide additional contextual information extending beyond the 
superpixel itself.
A subset of 40 ‘training’ images was then identified for the pathologist to interactively train a random trees 
classifier to distinguish between tissue areas comprising tumor epithelium, stroma and ‘other’ (e.g. whitespace, 
mucin, normal muscle or necrosis). This required drawing around regions containing tissue of each class and 
annotating these accordingly. During this process, QuPath used all available features to train the classifier in a 
background process and thereby provide immediate feedback on classification performance. Once the classifica-
tion was considered adequate across the training images, the classifier was applied to all images within the set and 
the total area of superpixels for each class was exported. The tumor stromal percentage (TSP) was then calculated 
as
= + ×TSP AS/(AE AS) 100 %
where AS represents the total area classified as stroma, and AE represents the total area classified as epithelium.
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